Anti-FAP monoclonal antibody F19-I-131

N/A

Report date: 2025/11/24 17:27:54

Base Information

Drug NameAnti-FAP monoclonal antibody F19-I-131
Drug Alias NameF19 monoclonal antibody I-131Anti-fibroblast activation protein monoclonal antibody F19
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive therapeutic agent +[5] 
Mechanisms of ActionFibroblast activation protein alpha antagonists
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer CenterC.H. Boehringer Sohn Ag & Co. KgLudwig Institute For Cancer Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. KgMemorial Sloan Kettering Cancer CenterLudwig Institute For Cancer Research
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A